nue life health Raises $3.3M for Psychedelics Mental Wellness Platform

NUE Life Health: Pioneering a New Approach to Mental Wellness

A U.S.-based telemedicine startup, NUE Life Health, is in the process of developing an innovative mental wellness solution. This next-generation system integrates psychedelic-assisted therapies with a sophisticated application powered by a graph database.

Seed Funding and Investor Base

The Miami-headquartered company has successfully secured $3.3 million in seed funding. This investment comes from a group of prominent individuals including Jack Abraham (Atomic Ventures, Hims), Shervin Pishevar (formerly of Sherpa Ventures, UBER), Martin Varsavsky (Prelude Fertility, Overture), Jon Oringer (Shutterstock, Pareto Holdings), James Bailey, and Christina Getty.

Notably, all of these investors represent the recent trend of technology leaders relocating from Silicon Valley to Miami.

Current Operations and Expansion Plans

Currently, NUE Life Health is providing services in California, Texas, and Florida. The company has ambitious plans to broaden its reach and extend its platform’s availability throughout the entire United States.

Core Treatment Offerings

The platform will feature at-home ketamine therapy, recognized as a rapidly effective antidepressant. This will be combined with music therapy and a data-driven methodology to optimize patient outcomes.

Research Supporting Psychedelic Therapies

NUE Life highlights research conducted by institutions like Johns Hopkins in Baltimore and Imperial College in London. Studies on MDMA and psilocybin-assisted psychotherapy suggest these treatments may offer “safe alternatives” for addressing mental health challenges.

CEO's Vision for Holistic Care

Juan Pablo Cappello, CEO of NUE Life, emphasized that ketamine and psychedelic therapies are viewed as catalysts for positive change. He stated NUE Life is dedicated to fostering community and connection for its members through its digital platform, even after the immediate effects of therapy subside.

Leveraging Technology for Personalized Treatment

Demian Bellumio, co-founder and CTO of NUE Life Health, explained that the digital platform will utilize Knowledge Graphs and AI. This technology will enable the delivery of personalized, evidence-based therapies, adopting a comprehensive approach to patient care.

The company’s HIPAA-compliant health platform is scheduled for launch in late summer of 2021.

Addressing a Critical Need

Christina Getty, a co-founder and investor, underscored the urgency of addressing mental health issues. She noted that one in five women in the U.S. relies on antidepressants daily, and tragically, 22 veterans are lost to suicide each day, motivating the launch of NUE Life.

The Growing Psychedelic Medicine Landscape

NUE Life’s emergence coincides with the public offerings of other key players in the psychedelic medicine field, such as MindMed and ATAI.

The Power of Knowledge Graphs and Integrated Psychiatry

Bellumio detailed how the platform constructs a comprehensive “knowledge graph” for each patient. This detailed profile allows for a thorough understanding of the individual, facilitating accurate diagnosis and treatment using an approach known as integrated psychiatry.

AI algorithms are then employed to personalize recommendations, encompassing treatment options, supplemental suggestions, and curated music selections for use during therapy. A dedicated, proprietary music streaming service will be integrated into the platform.

Bellumio’s Expertise and Industry Adoption

Bellumio’s prior experience includes work with graph databases at Accenture, where he led the Knowledge Graph Center of Excellence for two years, and at NEORIS. This technology is also utilized by United Healthcare within its “Connected Healthcare” platform.